

New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023

Lund, April 27 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data from the ongoing study with tasquinimod, a small molecule immunomodulator, in multiple myeloma will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, 2-6 June, 2023.

The poster will present interim results of safety and preliminary activity in the phase 1b dose escalation trial of tasquinimod as single agent and tasquinimod in combination with ixazomib, lenalidomide and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. The study (NCT04405167) is conducted at Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Abstracts will be released on meetings.asco.org May 25 at 5:00 PM (ET).

Details on the presentation:

- **Abstract Title:** Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM)
- **Session Title:** Hematologic Malignancies - Plasma Cell Dyscrasia
- **Abstract Number:** 8042
- **Session Date and Time:** June 5, 2023, 8:00 AM-11:00 AM (ET)

For further information, please contact:

Helén Tuveßon, CEO, +46 46 19 21 56, helen.tuveßon@activebiotech.com

Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

About tasquinimod

Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for hematological malignances, in the first step multiple myeloma. Tasquinimod has previously been studied as an anti-cancer agent in patients with solid cancers, including a phase III randomized trial in patients with metastatic prostate cancer. The tolerability of tasquinimod is well-characterized based on these previous experiences. Tasquinimod has demonstrated a clear therapeutic potential in preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy. A clinical Phase Ib/IIa study is ongoing with tasquinimod in relapsed or refractory multiple myeloma.

Attachments

New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023